Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Comprehensive transcriptomic characterization of hepatic expression signatures affected by guanine nucleotide binding protein (G protein) alpha 12 knockout

ABSTRACT: Heterotrimeric guanine nucleotide-binding proteins (G proteins) transmit extracellular signals from cell surface G protein-coupled receptors to intracellular effector molecules. Of the G proteins, Gα12 has attracted particular interest as the gep oncogene in cancer research because it promotes the growth and oncogenic transformation of fibroblasts and is invoked in tumorigenesis. In our findings, Gα12 expression was higher in HCC than surrounding non-tumorous tissue. Results provide information on the role of Gα12 in HCC progression. cDNA microarrays analyses using liver samples obtained from WT and Gα12-knockout mice enabled us to extract the predominant processes affected by a deficiency of Gα12, which include cellular response to stress, cell proliferation, actin cytoskeleton organization, and cellular component biogenesis.

ORGANISM(S): Mus musculus

PROVIDER: GSE51694 | GEO | 2019/07/18

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Profiling of microRNA expression in hepatocellular carcinoma cells with overexpression of G protein alpha 12 active mutant

2014-02-04 | GSE44079 | GEO

Gene expression data from acetaminophen-induced toxicity in wild-type and Gα12 knockout mice

Project description:Gα12 is an alpha subunit of heterotrimeric G proteins that activates the downstream pathways from G protein-coupled receptor (GPCR) signals. Gα12 overexpression enhances hepatocellular carcinoma (HCC) malignancy, promoting cancer migration and microvascular invasion. Also, it activates hepatic stellate cells (HSCs) and thereby facilitates the progression of liver fibrosis. However, upregulated Gα12 in hepatocytes by acetaminophen (APAP) mechanically has been scarcely explored. This study provides an evaluation of changes in gene expression using liver samples obtained from WT and Gα12KO mice treated with APAP.

2024-04-21 | GSE173595 | GEO

Profiling of microRNA expression in hepatocellular carcinoma cells with overexpression of G protein alpha 12 active mutant

Project description:Heterotrimeric guanine nucleotide-binding proteins (G proteins) transmit extracellular signals from cell surface G protein-coupled receptors to intracellular effector molecules. Attention has been paid to the GM-NM-112 family members because they mediate cell invasion, migration, and tumorigenesis. In our findings, GM-NM-112 levels were higher in human HCCs than non-tumorous liver tissues. Array analyses using Huh7 cells stably transfected with GM-NM-112QL (an active mutant form) enabled us to extract the microRNAs dysregulated by GM-NM-112 active mutant. Of them, miR-122 was most greatly decreased. In addition, we found decreases of miR-200b/a, miR-192/215 levels. Dysregulation of the microRNAs changed the levels of key proteins associated with HCC cell migration/invasion. Huh7 hepatoma cells were transfected with pCMV or the plasmid encoding for activated mutant of GM-NM-112 (GM-NM-112QL). Stable transfectants were selected by incubating the cells in culture medium containing Geneticin for 3 weeks. We performed a miRNA microarray for the identification of global microRNA expression changes using WT-Huh7 and Huh7-GM-NM-112QL cells. RNA for each set was harvested from quadruple plates.

2014-02-04 | E-GEOD-44079 | biostudies-arrayexpress

Gene expression profiling of 18 hepatocellular carcinoma and adjacent non-tumorous liver tissue

Project description:These paired HCC and non-tumorous liver tissues were used to determine highly differentially expressed genes in HCC and non-tumorous liver tissue. Hepatocellular carcinoma (HCC) is a malignancy with poor survival outcome. Genes showing extreme differential expression between paired human HCC and adjacent non-tumorous liver tissue were investigated. PLVAP was identified as a gene specifically expressed in vascular endothelial cells of HCC but not in non-tumorous liver tissues. This finding was confirmed by RT-PCR analysis of micro-dissected cells and immunohistochemical staining of tissue sections. A recombinant monoclonal anti-PLVAP Fab fragment co-expressing extracellular domain of human tissue factor (TF) was developed. The potential therapeutic effect and toxicity to treat HCC were studied using a Hep3B HCC xenograft model in SCID mice. Infusion of recombinant monoclonal anti-PLVAP Fab-TF into the tumor feeding artery induced tumor vascular thrombosis and extensive tumor necrosis at doses between 2.5 µg and 12 µg. Tumor growth was suppressed for 40 days after a single treatment. Systemic administration did not induce tumor necrosis. Little systemic toxicity was noted for this therapeutic agent. The results of this study suggest that anti-PLVAP Fab-TF may be used to treat HCC cases for which transcatheter arterial chemoembolization (TACE) is currently used, but without major drawbacks of TACE. Anti-PLVAP Fab-TF may improve therapeutic outcome and be a viable therapeutic agent in patients with more advanced disease and compromised liver function. Frozen hepatocellular carcinoma and adjacent non-tumorous liver tissues were used for gnee expression profiling study. Affymetrix U133A genechips were used for gene expression profiling. This dataset is part of the TransQST collection.

2015-01-01 | E-GEOD-60502 | biostudies-arrayexpress

Expression profile of Hepatocellular Carcinoma

Project description:Expression profiling of tumor and adjacent non-tumorous tissues of Hepatocellular Carcinoma (HCC) patients. Illumina HumanHT-12 V4.0 expression beadchip was used to obtain expression profiles across more than 31,000 annotated genes. Samples included 59 tumors and 59 adjacent non-tumorous samples. Total RNA obtained from the 39 tumors and 39 adjacent non-tumorous samples

2014-12-10 | E-GEOD-57957 | biostudies-arrayexpress

Gene expression profiling of 18 hepatocellular carcinoma and adjacent non-tumorous liver tissue

Project description:These paired HCC and non-tumorous liver tissues were used to determine highly dfferentially expressed genes in HCC and non-tumorous liver tissue. Hepatocellular carcinoma (HCC) is a malignancy with poor survival outcome. Genes showing extreme differential expression between paired human HCC and adjacent non-tumorous liver tissue were investigated. PLVAP was identified as a gene specifically expressed in vascular endothelial cells of HCC but not in non-tumorous liver tissues. This finding was confirmed by RT-PCR analysis of micro-dissected cells and immunohistochemical staining of tissue sections. A recombinant monoclonal anti-PLVAP Fab fragment co-expressing extracellular domain of human tissue factor (TF) was developed. The potential therapeutic effect and toxicity to treat HCC were studied using a Hep3B HCC xenograft model in SCID mice. Infusion of recombinant monoclonal anti-PLVAP Fab-TF into the tumor feeding artery induced tumor vascular thrombosis and extensive tumor necrosis at doses between 2.5 µg and 12 µg. Tumor growth was suppressed for 40 days after a single treatment. Systemic administration did not induce tumor necrosis. Little systemic toxicity was noted for this therapeutic agent. The results of this study suggest that anti-PLVAP Fab-TF may be used to treat HCC cases for which transcatheter arterial chemoembolization (TACE) is currently used, but without major drawbacks of TACE. Anti-PLVAP Fab-TF may improve therapeutic outcome and be a viable therapeutic agent in patients with more advanced disease and compromised liver function.

2015-01-01 | GSE60502 | GEO

Expression profile of Hepatocellular Carcinoma

2014-12-10 | GSE57957 | GEO

Methylation profile of Hepatocellular Carcinoma

Project description:DNA methylation profiling of tumor and adjacent non-tumorous tissues of Hepatocellular Carcinoma (HCC) patients. The Illumina Infinium 27k Human DNA methylation Beadchip v1.2 was used to obtain DNA methylation profiles across approximately 27,000 CpGs. Samples included 59 tumors and 59 adjacent non-tumorous samples.

2014-12-10 | GSE57956 | GEO

Transcriptome analysis in hepatocellular carcinoma (HCC) tissues

Project description:We report the application of RNA sequencing technology for high-throughput profiling in HCC tissues. In the present study, to explore novel biomarkers of HCC, we firstly explored the expression profiles of mRNAs and miRNAs in three pairs of HCC patients (tumor tissues and non-tumorous tissues) by high-throughput RNA sequencing. A total of 1024 mRNAs were found to be significantly dysregulated (636 up-regulated and 388 down-regulated), 50 miRNAs were found to be significantly dysregulated (27 up-regulated and 23 down-regulated) in the HCC tissues compared with the non-tumorous tissues.Then validae the differentially expressed miRNAs by qRT-PCR in HCC tissues and serum. This study provides a framework for the application of miRNAs to be ideal biomarkers for HCC.

2023-02-28 | GSE146719 | GEO

HCC progression - Quantitative proteome analysis reveals the correlation between endocytosis-associated proteins and hepatocellular carcinoma dedifferentiation

Project description:Endocytosis is a cellular function which is likely to take part in HCC development due to its important role in regulating the abundances of vital signaling receptors. In this study, we aimed to investigate the expression of endocytosis-associated proteins in HCCs with various differentiation grades. Therefore, we analyzed 36 tissue specimens from HCC patients via label-free LC-MS/MS including 19 HCC tissue samples with different degrees of histological grades and 17 corresponding non-tumorous tissue controls. Following label-free analysis the abundances of SCAMP3 and CLTC were immunohistochemically examined in tissue sections of 84 HCC patients. We demonstrate the novel association of several endocytosis-associated proteins, in particular SCAMP3 with HCC progression.

2016-09-27 | PXD003552 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data